Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Total Liabilities (2020 - 2026)

Immuneering's Total Liabilities history spans 7 years, with the latest figure at $8.3 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 6.19% to $8.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.3 million, a 6.19% decrease, with the full-year FY2025 number at $13.5 million, up 19.18% from a year prior.
  • Total Liabilities came in at $8.3 million for Q1 2026, down from $13.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $13.5 million in Q4 2025, with the low at $8.3 million in Q1 2026.
  • Historically, Total Liabilities has averaged $10.6 million across 5 years, with a median of $10.8 million in 2024.
  • Peak annual rise in Total Liabilities hit 105.23% in 2022, while the deepest fall reached 70.59% in 2022.
  • Year by year, Total Liabilities stood at $12.5 million in 2022, then decreased by 4.06% to $12.0 million in 2023, then decreased by 5.66% to $11.3 million in 2024, then increased by 19.18% to $13.5 million in 2025, then crashed by 38.59% to $8.3 million in 2026.
  • Business Quant data shows Total Liabilities for IMRX at $8.3 million in Q1 2026, $13.5 million in Q4 2025, and $13.1 million in Q3 2025.